Every Form 4 that Harvard Bioscience Inc (HBIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HBIO filings page.
Eade Katherine A. reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Katherine A. Eade received an award of 16,556 restricted stock units of common stock at no cost. The RSUs vest in full either immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first. After this grant, she beneficially owns 58,669 shares, including 42,113 shares of common stock adjusted for a 10-for-1 reverse stock split that took effect on March 13, 2026.
Snider William reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director William Snider received an equity grant in the form of 16,556 restricted stock units of common stock. The award vests in full immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first, providing time-based compensation for board service.
After this grant, Snider holds a total of 48,556 common share equivalents, including the new award, previously purchased common shares from March 16 and March 17, 2026, and 11,000 restricted stock units scheduled to fully vest on December 17, 2026. The filing also notes that the 11,000 restricted stock units were adjusted to reflect a 10-for-1 reverse stock split that took place on March 13, 2026.
DENELSKY STEPHEN J reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Stephen J. Denelsky received a grant of 16,556 restricted stock units (RSUs) of common stock. The award vests in full either immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first.
After this award, Denelsky holds 37,556 shares and RSUs in total, including 10,000 shares of common stock purchased on March 17, 2026 and 11,000 RSUs scheduled to fully vest on September 5, 2026. The filing notes that these 11,000 RSUs were adjusted to reflect a 10-for-1 reverse stock split that took place on March 13, 2026.
Gagnon Robert E. reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Robert E. Gagnon received an equity grant of 16,556 restricted stock units (RSUs) of common stock. The award vests in full immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first.
After this grant, Gagnon beneficially owns 27,556 common shares, including 11,000 shares previously issued upon vesting of earlier RSUs. Those 11,000 shares were adjusted to reflect a 10-for-1 reverse stock split of Harvard Bioscience common stock that took place on March 13, 2026.
Benson Seth Benjamin reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Seth Benjamin Benson received a grant of 16,556 restricted stock units of common stock, awarded at a price of $0.0000 per share. This equity award will vest in full immediately before the company’s next annual meeting or one year from the grant date, whichever comes first.
After this grant, Benson directly holds 27,556 shares of common stock, including the new award and 11,000 shares already beneficially owned. The filing also notes a 10-for-1 reverse stock split of Harvard Bioscience common stock that occurred on March 13, 2026, which adjusted previously reported award amounts.
Harvard Bioscience Chief Financial Officer Mark T. Frost reported an equity compensation grant rather than a market trade. He acquired 30,000 restricted stock units (RSUs) at no cost, which will vest in three equal installments on March 20, 2027, 2028, and 2029, subject to his award agreement. After this grant, he is shown with 47,500 common stock equivalents, including 5,000 shares purchased on March 16, 2026, 10,000 additional RSUs scheduled to vest on May 12, 2026, and 2,500 shares of common stock beneficially owned. The filing also notes that these RSU and share counts were adjusted to reflect a 10-for-1 reverse stock split that took effect on March 13, 2026.
Harvard Bioscience Chief Financial Officer Mark T. Frost bought 5,000 shares of common stock in an open-market purchase at $5.00 per share. Following this transaction, he directly owns a total of 17,500 shares, including 10,000 restricted stock units scheduled to vest on May 12, 2026.
Duke John D reported acquisition or exercise transactions in this Form 4 filing.
HARVARD BIOSCIENCE INC reported that Chief Executive Officer and director John D. Duke received a grant of 75,000 shares of Common Stock on 2026-03-20. The award was reported at a price of $0.0000 per share, indicating a compensation-related grant rather than a market purchase. Following this transaction, his directly owned Common Stock holdings increased to 180,000 shares.
Harvard Bioscience director Stephen J. Denelsky bought 10,000 shares of common stock in an open-market transaction at $4.87 per share. After this purchase on March 17, 2026, he directly holds 21,000 shares, including 11,000 restricted stock units scheduled to fully vest on September 5, 2026.
The footnotes also note that on March 13, 2026, Harvard Bioscience completed a 10-for-1 reverse stock split, and the 11,000 restricted stock units were adjusted from a previously reported 110,000 units to reflect this split.
Harvard Bioscience director William Snider reported open-market purchases of company stock. On March 16, 2026, he bought 12,525 shares of common stock at a weighted average price of $4.99 per share, with actual trade prices ranging from $4.80 to $4.95. On March 17, 2026, he bought an additional 8,475 shares at a weighted average price of $4.85, with individual trades between $4.85 and $5.00. Following these transactions, he directly holds 32,000 shares of common stock, plus 11,000 restricted stock units that fully vest on December 17, 2026. The filing notes a 10-for-1 reverse stock split of Harvard Bioscience common stock on March 13, 2026, which reduced the previously reported 110,000 restricted stock units to 11,000.
Harvard Bioscience Chief Executive Officer John D. Duke bought 5,000 shares of common stock in an open-market purchase at $5.01 per share on March 16, 2026, bringing his directly held common stock to 105,000 shares.
His reported holdings include 50,000 restricted stock units that vest in three equal installments on August 8, 2026, 2027 and 2028, plus 50,000 performance-based RSUs that may vest based on relative total shareholder return versus the Russell 2000 index over the period from August 8, 2025 to the earlier of July 30, 2028 or a change of control, with a maximum payout of 150% of the target RSU amount. The RSU figures have been adjusted to reflect a 10-for-1 reverse stock split on March 13, 2026.
Stephen DeNelsky, a director of Harvard Bioscience, Inc. (HBIO), reported an award of 110,000 restricted stock units on 09/05/2025. The Form 4 shows the units were recorded as acquired at a price of $0.00 and are held directly, bringing the reporting person’s beneficial ownership following the transaction to 110,000 shares. The filing explains these restricted stock units fully vest on 09/05/2026. The form is signed by the reporting person on 10/07/2025.